Learn how to report serious adverse events for generic drugs. Discover why generics are underreported, the regulatory requirements, and practical steps for healthcare providers to ensure accurate safety tracking.
Read More
Prescribers have varying concerns about substituting generic versions of Narrow Therapeutic Index (NTI) drugs due to risks of adverse effects. Key factors include regulatory guidelines, specialty-specific practices, and communication between pharmacists and doctors. Real-world data shows substitution impacts on patient monitoring and costs. Current trends point to evolving policies and increased reliance on clinical evidence.
Read More